Many countries around the world are already overwhelmed by the Covid-19 pandemic. This has made scientists and researchers find a proper solution to combat the pandemic. As a result, countries have developed vaccines which are currently in use in bid to control the spread of the Coronavirus disease. However, some of the vaccines are ineffective with some of them having low supply.
As the search for the cure of the disease is still underway, a new drug is being developed which is set to be used in the treatment of coronavirus.
The drug will be used to treat patients who are not battling severe cases of Covid-19. The drug is expected to undergo tests and trials in thirteen (13) different countries in African. Among the countries selected, Kenya is one of them. This new drug is called ANTICOV. The technology used in development of this drug involve combining two other drugs which include Nitazoxanide and Ciclesonide using certain clinical ratios and techniques.
Nitazoxanide is an old drug which has been used for many years in the treatment of diarrhea. It is often used in eliminating intestinal germs.
On the other hand, Ciclesonide has respiratory treatment properties. The drug has been in use for a long time and helps patients suffering from asthma, chest tightness and other respiratory problems recover. These two drugs have been combined and modified scientifically to help in the treatment of coronavirus disease.
The new drug is now at the trial stages and the trial experiments are being carried out by different organizations. If ANTICOV will be successful in the trials, it will be used in the treatment of patients in the early stages of the disease to prevent future viral regeneration. Additionally, the body will be able to retain antibodies which will boost the immunity.
Another benefit what will come with this drug will be significant reduction of the number of Covid-19 patients in the ICUs. If it will be effective, the drug will also help in reducing severe cases of infections as well as reducing the fatalities.
The countries which will participate in the trials have already been registered in DRC. Among the countries registered to take part in this important task include Ethiopia, Equatorial Guinea, Ghana, Mozambique, Mali, Sudan, Uganda as well as Kenya.